Last reviewed · How we verify

NCT03422523: ARGO

Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy

Terminated Phase 2 Last updated 22 August 2022
What this trial tests

Phase 2 trial testing Atezolizumab in Diffuse Large B Cell Lymphoma in 53 participants. Terminated before completion.

Timeline
9 May 2018
Primary endpoint
31 January 2021
18 November 2021

Quick facts

Lead sponsorUniversity Hospital Southampton NHS Foundation Trust
PhasePhase 2
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment53
Start date9 May 2018
Primary completion31 January 2021
Estimated completion18 November 2021
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital Southampton NHS Foundation Trust

Who can join

16 and older, any sex, with Diffuse Large B Cell Lymphoma or Relapsed Diffuse Large B-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the addition of Atezolizumab to current therapy of Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) that are not candidates for high-dose therapy. All patients will receive one cycle of R-GemOx. Three quarters of patients (Arm B) will go on to have a further 5 cycles (every 14 days) of R-GemOx with Atezolizumab, with one quarter of patients (Arm A) continuing with 5 cycles of R-GemOx. The patients in Arm B will continue to have Atezolizumab every 21 days for 8 cycles whilst Arm A patients will enter an observational phase during this time. Follow up will begin at 12 months from initial treatment until month 32.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.
    Zhang J, Zhang J, Medeiros LJ, Young KH. · · 2018 · cited 65× · PMID 30250823 · DOI 10.3389/fonc.2018.00351
  2. Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma.
    Song MK, Park BB, Uhm J. · · 2019 · cited 52× · PMID 30884772 · DOI 10.3390/ijms20061326
  3. Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations.
    Tan WK, Segal BD, Curtis MD, Baxi SS, et al · · 2022 · cited 12× · PMID 36186544 · DOI 10.1016/j.conctc.2022.101000
  4. B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?
    Zhang W, Qiu Y, Xie X, Fu Y, et al · · 2021 · cited 7× · PMID 33869045 · DOI 10.3389/fonc.2021.647526
  5. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials.
    Guan J, Zhang J, Zhang X, Yuan Z, et al · · 2022 · cited 5× · PMID 36550903 · DOI 10.1097/md.0000000000032333
  6. Comparison of anti-PD-1/PD-L1-based regimens in relapsed/refractory diffuse large B-cell lymphoma: a meta-analysis.
    Jiang W, Wen T, Liu P. · · 2025 · cited 1× · PMID 41282995 · DOI 10.7717/peerj.20314

Verify or expand the search:

Other trials of Atezolizumab

Trials testing the same drug.

Other recruiting trials for Diffuse Large B Cell Lymphoma

Currently open trials in the same condition.

Other University Hospital Southampton NHS Foundation Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03422523.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing